Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Phio Pharmaceuticals Corporation | PHIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.671 | 04:03:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.671 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.50 - 6.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.671 | USD |
Phio Pharmaceuticals Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.64M | 2.44M | - | 0 | -10.83M | -4.43 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Phio Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHIO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.6283 | 1.05 | 0.604849 | 0.8156303 | 1,630,607 | 0.0427 | 6.80% |
| 1 Month | 0.73 | 1.05 | 0.604849 | 0.8021652 | 476,554 | -0.059 | -8.08% |
| 3 Months | 0.60 | 1.15 | 0.5459 | 0.8602989 | 431,872 | 0.071 | 11.83% |
| 6 Months | 1.23 | 2.09 | 0.50 | 1.16 | 514,268 | -0.559 | -45.45% |
| 1 Year | 3.25 | 6.85 | 0.50 | 2.37 | 629,962 | -2.58 | -79.35% |
| 3 Years | 28.20 | 34.20 | 0.50 | 15.65 | 716,868 | -27.53 | -97.62% |
| 5 Years | 5.76 | 130.20 | 0.50 | 19.01 | 728,363 | -5.09 | -88.35% |
Phio Pharmaceuticals Description
| Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. |
